{"id":"nct:NCT03435796","kind":"trial","title":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","authors":["Celgene"],"author_count":1,"year":2018,"published":"2018-02-19","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT03435796","source_url":"https://clinicaltrials.gov/study/NCT03435796","archive_url":"https://space-kitty.com/papers/nct:NCT03435796","updated":"2026-09-18","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Neoplasms"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE2, PHASE3","study_type":"INTERVENTIONAL","enrollment":1541,"sponsor":"Celgene","conditions":["Neoplasms"],"interventions":["GENETIC: Gene-modified (GM) T cell therapy"],"start_date":"2018-07-19","start_date_type":"ACTUAL","primary_completion_date":"2043-05-29","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"},{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}